What is pseudo Meigs syndrome?

Pseudo Meigs syndrome refers to a clinical syndrome of pleural effusion, ascites associated with an ovarian tumor that is not a fibroma or a fibroma-like tumor.

How does ovarian cancer cause ascites?

According to Cancer Research UK, a charity based in the United Kingdom, ascites in ovarian cancer may form when cancer cells spread to the peritoneum, which is the lining of the abdomen. The cancer cells can irritate the lining, causing fluid to build up.

What is malignant effusion?

A malignant pleural effusion (MPE) is the build up of fluid and cancer cells that collects between the chest wall and the lung. This can cause you to feel short of breath and/or have chest discomfort. It is a fairly common complication in a number of different cancers.

Does Chemo stop pleural effusion?

Malignant pleural effusion (MPE) occurs frequently in patients with advanced malignancies, and is associated with a short life expectancy and may cause considerable morbidity. Most effusions do not respond to systemic chemotherapy, thus treatment is generally palliative.

Why do you get MEIG syndrome?

Meigs’ syndrome is diagnosed based on a triad of an ovarian fibroma, pleural effusion and ascites. It resolves spontaneously after the resection of the fibroma. In 1852, Blin published the description of an ovarian fibroma with abdominal effusion in the Société de Biology de Paris (cited by Lallemand).

How do you treat MEIG syndrome?

Treatment of Meigs syndrome Exploratory laparotomy with surgical staging is the treatment of choice. Medical care of patients with Meigs syndrome is intended to provide symptomatic relief of ascites and pleural effusion by means of therapeutic paracentesis and thoracentesis.

What stage of ovarian cancer do you get ascites?

The presence of ascites is significantly associated with the extent of disease, with ascites present in >90% of patients with stage III and IV ovarian cancer.

Does ovarian cancer ascites go away?

Malignant ascites generally resolve when the underlying disease is successfully treated. EOC is managed by cytoreductive surgery followed by platinum-based chemotherapy and the expected response rate of primary therapy is more than 70%.